Pilot Study of the Use of ULTRABRAID PLUS SUTURE in the Repair of Tears of the Rotator Cuff
Launched by SMITH & NEPHEW, INC. · Jan 10, 2013
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of this two-arm, randomized, single-blind pilot study is to obtain safety data on the use of the ULTRABRAID Plus Suture and to assess the preliminary effectiveness of the use of the ULTRABRAID Plus Suture in comparison to the ULTRABRAID Suture in subjects undergoing rotator cuff repair. The primary endpoint of the 6-month postoperative analysis is to assess rotator cuff integrity at 6 months, defined as the proportion of subjects with a re-tear of the rotator cuff as measured by high-resolution ultrasound.
Secondary endpoints include:
rotator cuff integrity at the ot...
Gender
ALL
Eligibility criteria
- Inclusion Criteria (Subjects must meet ALL of the following criteria):
- • Male or female, aged 18 to 70 years at the time of surgery
- • Willing and able to give voluntary informed consent to participate in this investigation
- • Small (\<1cm), Medium (1-3cm) or large (\>3-5cm) tear of the supraspinatus tendon, which may or may not include the infraspinatus tendon of the rotator cuff. Tear size will be based on area of longest dimension as evidenced by clinical examination and diagnostic imaging prior to surgery, with the definitive measurement confirmed at surgery
- • Tear requires repair within two years of initial diagnosis
- • Tear must be anatomically repairable (must be able to get tendon back to the medial position on the footprint and at least back to the tuberosity)
- • Willing and able, in the opinion of the Investigator, to cooperate with study procedures, and willing to return to study site for physical therapy and all post-operative study visits
- Exclusion Criteria (Subjects must not meet ANY of the following criteria):
- • Tears involving tendons other than the supraspinatus and infraspinatus
- • Partial thickness tears of the rotator cuff (tear must be full thickness)
- • Evidence of acute trauma including fracture or dislocation of the shoulder joint
- • Chronic retraction
- • Evidence of active infection, osteomyelitis, sepsis or distant infection which could spread to the index joint
- • Subject has had previous rotator cuff, arthroplasty or fracture procedures on the operative shoulder
- • Subject has had acromioplasty or diagnostic arthroscopy on the operative shoulder within one (1) year prior to scheduled surgery date
- • Evidence of osteomalacia or other metabolic bone disorder(s) which may impair bone or soft tissue function
- • Evidence of other significant shoulder pathology including (Type II-IV lesion, Bankart lesion, Hill Sachs lesion)
- • Patient has grade 4 changes to articular cartilage in operative shoulder
- • Inflammatory arthropathies
- • Significant muscle paralysis of the shoulder girdle.
- • Painful pathologies of the cervical spine
- • Comminuted bone surface, which would compromise secure anchor fixation.
- • Subject has a known sensitivity to implant materials, including sodium butyrate.
- • Non-surgical rotator cuff associated treatment, such as corticosteroid injection, within one (1) month prior to scheduled surgery date
- • Participating in another investigational trial or ongoing study that would interfere with the assessment of the primary and secondary outcomes
- • Female patient who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods
- • Currently known to abuse drugs or alcohol which could affect follow-up care or treatment outcomes
- • Current smoker
- • Major psychiatric illness, developmental handicap or inability to read and understand the English language
- • Major medical illness that would preclude undergoing surgery
- • Known to be involved in any active injury litigation claims relating to the study shoulder
- • Unwilling or unable to be assessed according to study protocol for one year following surgery
- • Patient requires a concomitant SLAP repair procedure in operative shoulder
- • Surgeon plans to use transosseous sutures in the study procedure
- • Surgeon plans to use a Platelet Rich Plasma product or another therapy intended to augment healing of the rotator cuff in the study procedure
- • Protocol specified surgical technique cannot be followed for this subject
- • Rotator cuff repair will be done via open (as opposed to arthroscopic) procedure
- • Any other reason (in the judgment of the investigator)
About Smith & Nephew, Inc.
Smith & Nephew, Inc. is a global medical technology company dedicated to transforming the experience of surgery for healthcare professionals and their patients. With a rich history of innovation, Smith & Nephew develops advanced products and solutions across various medical fields, including orthopedics, wound care, and sports medicine. Committed to improving patient outcomes, the company invests significantly in research and development, conducting rigorous clinical trials to ensure the safety and efficacy of its products. By collaborating with healthcare professionals and industry partners, Smith & Nephew strives to deliver cutting-edge technologies that enhance surgical procedures and promote faster recovery times.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Burlington, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Robert Litchfield, MD, FRCSC
Principal Investigator
Fowler Kennedy Sports Medicine Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials